Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Bepirovirsen Liver Biopsy study'. The following are the other relevant details related to the tria... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel a... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC ... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyros... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Ad... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'Evaluating the efficacy and safety of Platelet Rich Plasma for patients with Peyronie’s disease: A... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'SURFactant Administration by SUPraglottic Airway (the SURFSUP Trial)'. The following are the other... Read More
Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with ... Read More